Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

ADIPOQ polymorphisms are associated with insulin resistance in Japanese women.

Kitamoto A, Kitamoto T, So R, Matsuo T, Nakata Y, Hyogo H, Ochi H, Nakamura T, Kamohara S, Miyatake N, Kotani K, Mineo I, Wada J, Ogawa Y, Yoneda M, Nakajima A, Funahashi T, Miyazaki S, Tokunaga K, Masuzaki H, Ueno T, Chayama K, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Sakata T, Tanaka K, Matsuzawa Y, Hotta K.

Endocr J. 2015 Mar 31. [Epub ahead of print]

2.

Biphasic effect of alcohol intake on the development of fatty liver disease.

Takahashi H, Ono M, Hyogo H, Tsuji C, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T, Anzai K, Eguchi Y.

J Gastroenterol. 2015 Mar 3. [Epub ahead of print]

PMID:
25733100
3.

Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.

Takeuchi M, Sakasai-Sakai A, Takata T, Ueda T, Takino J, Tsutsumi M, Hyogo H, Yamagishi S.

Med Hypotheses. 2015 May;84(5):490-3. doi: 10.1016/j.mehy.2015.02.002. Epub 2015 Feb 10.

4.

Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Takeuchi M, Takino J, Sakasai-Sakai A, Takata T, Ueda T, Tsutsumi M, Hyogo H, Yamagishi S.

World J Hepatol. 2014 Dec 27;6(12):880-93. doi: 10.4254/wjh.v6.i12.880. Review.

5.

LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.

Imajo K, Hyogo H, Yoneda M, Honda Y, Kessoku T, Tomeno W, Ogawa Y, Taguri M, Mawatari H, Nozaki Y, Fujita K, Kirikoshi H, Saito S, Sumida Y, Ono M, Wada K, Nakajima A, Eguchi Y.

PLoS One. 2014 Dec 26;9(12):e115403. doi: 10.1371/journal.pone.0115403. eCollection 2014.

6.

Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation.

Kawaoka T, Takahashi S, Kawakami Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Aikata H, Ishiyama K, Tashiro H, Ohdan H, Tanaka J, Chayama K.

Hepatol Res. 2014 Nov 5. doi: 10.1111/hepr.12447. [Epub ahead of print]

PMID:
25376902
7.

Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers.

Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K, Chayama K.

J Gastroenterol Hepatol. 2015 Apr;30(4):726-32. doi: 10.1111/jgh.12821.

PMID:
25311578
8.

Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Kan H, Yamagishi SI, Ojima A, Fukami K, Ueda S, Takeuchi M, Hyogo H, Aikata H, Chayama K.

J Clin Lab Anal. 2014 Sep 23. doi: 10.1002/jcla.21797. [Epub ahead of print]

PMID:
25252033
9.

A case of syndrome of inappropriate secretion of antidiuretic hormone following transarterial embolization with cisplatin.

Kan H, Kawaoka T, Kobayashi T, Hiramatsu A, Tsuge M, Imamura M, Hyogo H, Kawakami Y, Aikata H, Chayama K.

Nihon Shokakibyo Gakkai Zasshi. 2014 Sep;111(9):1805-10.

PMID:
25195966
10.

Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.

Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD).

World J Gastroenterol. 2014 Aug 7;20(29):10108-14. doi: 10.3748/wjg.v20.i29.10108.

11.

Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis.

Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K.

Hepatol Res. 2014 Aug 3. doi: 10.1111/hepr.12400. [Epub ahead of print]

PMID:
25088236
12.

Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

Fujino H, Kimura T, Aikata H, Miyaki D, Kawaoka T, Kan H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Takahashi S, Yoshimatsu R, Yamagami T, Kenjo M, Nagata Y, Awai K, Chayama K.

Hepatol Res. 2014 Jul 23. doi: 10.1111/hepr.12392. [Epub ahead of print]

PMID:
25052365
13.

Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report.

Honda Y, Kawaoka T, Aikata H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Naeshiro N, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Arihiro K, Chayama K.

Hepatol Res. 2014 Jul 17. doi: 10.1111/hepr.12391. [Epub ahead of print]

PMID:
25041322
14.

Insulin resistance correlated with the severity of liver histology in Japanese NAFLD patients: a multicenter retrospective study.

Kessoku T, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Kawaguchi T, Nakajima A; Japan Study Group of NAFLD.

J Clin Gastroenterol. 2015 Feb;49(2):169-70. doi: 10.1097/MCG.0000000000000186. No abstract available.

PMID:
25014241
15.

Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease.

Ishitobi T, Hyogo H, Kan H, Hiramatsu A, Arihiro K, Aikata H, Chayama K.

Hepatol Res. 2015 May;45(5):533-9. doi: 10.1111/hepr.12382. Epub 2014 Jul 18.

PMID:
24976364
16.

Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.

Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Chayama K.

Hepatogastroenterology. 2014 Mar-Apr;61(130):323-8.

PMID:
24901133
17.

Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease.

Nakamura A, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Okanoue T, Nakajima A, Maeda S, Terauchi Y.

J Diabetes Investig. 2013 Nov 27;4(6):651-8. doi: 10.1111/jdi.12101. Epub 2013 May 19.

18.

Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease.

Yoneda M, Thomas E, Sumida Y, Imajo K, Hyogo H, Fujii H, Ono M, Kawaguchi T, Eguchi Y, Nakajima A.

Clin Biochem. 2014 Aug;47(12):1138-9. doi: 10.1016/j.clinbiochem.2014.04.026. Epub 2014 May 4. No abstract available.

PMID:
24797484
19.

Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J).

Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K; Japan Study Group for NAFLD (JSG-NAFLD).

Hepatol Res. 2015 Mar;45(3):269-78. doi: 10.1111/hepr.12351. Epub 2014 May 28.

PMID:
24796231
20.

Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.

Kitamoto A, Kitamoto T, Nakamura T, Ogawa Y, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Nakao K, Sekine A, Chayama K, Nakajima A, Hotta K.

Endocr J. 2014;61(7):683-9. Epub 2014 May 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk